The media reports on research into Alzheimer’s disease, including expanding areas of study and the potential for a diabetes drug to help protect against the disease. USA Today and The Atlantic are covering developments in a scandal over Alzheimer’s key amyloid protein research.
NPR: Scientists map brain changes to better treat Alzheimer’s disease
After decades of focusing on the sticky amyloid plaques and tangled tau fibers associated with the disease, brain researchers are looking for other potential causes of impaired memory and thinking. That research is on full display this week at the Alzheimer’s Association’s international conference in San Diego, where sessions explore factors like genes, brain damage, clogged arteries and inflammation. (Hamilton, 8/1)
ScienceDaily: Diabetes drug may protect against Alzheimer’s disease
Mechanisms linked to a specific diabetes drug may also help protect against Alzheimer’s disease, according to a study from Karolinska Institutet in Sweden published in the journal Neurology. The results suggest that the drug’s target protein could be a promising candidate for the treatment of Alzheimer’s disease. (8/1)
CNN: The fight against Alzheimer’s: where are we?
With so many genes contributing to the development of Alzheimer’s disease and other types of dementia, scientists are convinced that each person’s journey may be different. “There’s a saying: once you’ve seen someone with Alzheimer’s disease, you’ve seen someone with Alzheimer’s disease,” said Dr. Richard Isaacson, director of the prevention clinic of Alzheimer’s disease at the Center for Brain Health at Schmidt College of Florida Atlantic University. Medicine. (LaMotte, 07/31)
And an Alzheimer’s research scandal continues to simmer –
USA Today: Alzheimer’s theory under scrutiny after research fraud accusation
The article centered on a Vanderbilt University neurologist’s investigation of images used in the 2006 research paper on the discovery of a type of protein called amyloid beta star 56. Dr. Matthew Schrag concluded that the published images used to support the research were likely altered, although he stopped unless he called the research fraudulent, noting that he had no access to the original unpublished images or the underlying data. His research was done outside of his duties at Vanderbilt University Medical Center. (Alltucker and Weintraub, 7/29)
The Atlantic: What an Alzheimer’s Disease Controversy Reveals About Academia
For scientists, publication in Nature is a career highlight. To make its pages, the work must be deemed exceptionally significant, with a potentially transformative impact on scientific understanding. In 2006, a study on Alzheimer’s disease conducted by lead author Sylvain Lesné met these criteria: it suggested a new cause of the disease, a molecule called Aβ*56, which would have caused symptoms of dementia in rats. . The study has since racked up more than 2,300 citations in the scientific literature and inspired years of follow-up work. But an investigation of the original paper and many others by Lesné, described last week in Science, identified many red flags indicating the possibility of data fraud. (Nature added a note to the document, saying the work is under investigation and its findings should be treated with caution.) (Grimes, 7/29)
In other scientific developments —
NBC News: World’s first HIV-to-HIV heart transplant performed at New York Hospital
The patient, a woman in her 60s, had advanced heart failure and received the donation, along with a concurrent kidney transplant, in early spring at Montefiore Health System in the Bronx, according to a news release. (Burke, 07/30)
Stat: Using a sticky, stretchy material, scientists design a continuous ultrasound system
It took hundreds of failed experiments, sticking gummy gels to all sorts of surfaces, for scientists at the Massachusetts Institute of Technology to get what they were looking for: a material so adhesive it could cement a device to the skin for two full days while remaining motionless. allow sound waves to pass. (Chen, 8/1)
The Washington Post: Finally, an easier way to prepare for a colonoscopy
Last year – in what experts believe could end the fear that keeps many people from getting this important screening – the Food and Drug Administration approved a regimen of pills, Sutab, which studies show works just as well. than liquid solutions – without the nasty flavor. It is a diet of 24 tablets: 12 tablets the day before and 12 the next day, several hours before the procedure. (Cimons, 07/31)
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news outlets. Sign up for an email subscription.